Aurora Mirabile



Dr. Aurora Mirabile is the head for the Head and Neck Cancer Diagnosis and Treatment Section in the Division of Medical Oncology at IRCCS Ospedale San Raffaele in Milan, Italy, and also a teacher in the School of Otolaryngology.

After graduating in Medicine and Surgery from the University of Milan Bicocca in 2006, she specialized with honors in Medical Oncology at the University of Milan in 2009.

From 2009 to 2014, she was a Medical Oncologist at SS Medical Treatment of Head and Neck Tumors at the National Cancer Institute in Milan, Italy. From 2015 to 2017, she was a Level I Medical Director of SC Medical Oncology at Azienda Ospedaliera Sant'Antonio Abate Gallarate (VA), ASST Valleolona, dealing mainly with cancers of the head and neck and gastroenteric district.

Since 2017, she has been employed under a freelance consulting contract at the Department of Medical Oncology, Ospedale San Raffaele in Milan, Italy, as a Referral for the diagnosis and treatment of head and neck district cancers, and from 2021 as the Head.

Over the years, Dr. Mirabile has developed a special interest in head and neck neoplasms, evidence-based medicine, clinical methodology in oncology, and quality of life. Specifically, her target organs are oral cavity (mouth), oropharynx (tongue base, tonsils and soft palate), nasopharynx (back of the nose), sinuses and nasal cavities, larynx, hypopharynx and salivary glands.

She is also responsible for the diagnostic/therapeutic pathway of these patients, collaborating with ENT surgeons and radiation therapists as well as radiologists, nuclear physicians, and anatomopathologists, to optimize their care plan and ensure access to more precise, specific, and effective technologies, modalities, and therapies. In addition, she coordinates the multidisciplinary activities of various specialties to support the patient (e.g., nutritionist, geriatrician, psychologist, dentist, vulnologist) so as to optimize quality of life and ensure the necessary care throughout the treatment pathway.

Dr. Mirabile is also Principal Investigator of phase III clinical trials with new biologic and immunotherapeutic drugs in both locally advanced and metastatic disease, so that patients can be given increasingly cutting-edge treatments.

She is an author and co-author of 52 publications for Extenso, abstracts and book chapters in international and national journals, as well as principal investigator and sub-investigator in more than 40 Clinical Trials in GCP. Dr. Mirabile is an active member of national and international oncology associations such as ESMO, AIOCC, AIOM, ECHNO, EORTC and NICSO.

Read moreRead less

Multimedia gallery

Do you need an appointment?

Contact us and we will take care of you.


Latest publications

Skeletal Muscle Depletion and Major Postoperative Complications in Locally-Advanced Head and Neck Cancer: A Comparison between Ultrasound of Rectus Femoris Muscle and Neck Cross-Sectional Imaging
Galli A, Colombo M. Prizio, Carrara G., Lira Luce F, Paesano PL, Della Vecchia G, Giordano L, Bondi S, Tulli M, Di Santo D, Mirabile A, et al.
What to Do and What Not to Do in the Management of Cancer Pain: A Physician Survey and Expert Recommendations
Bossi P, Antonuzzo A, Armento G, Consoli F, Giuliani J, Giusti R, Lucchesi M, Mirabile A, Palermo L, Scagliarini S.
A CT-Based Radiomic Signature Can Be Prognostic for 10-Months Overall Survival in Metastatic Tumors Treated with Nivolumab: An Exploratory Study
Corino VDA, Bologna M, Calareso G, Licitra L, Ghi M, Rinaldi G, Caponigro F, Morelli F, Airoldi M, Allegrini G, Cassano A, Ferrari D, Mirabile A, Tosoni A, Galizia D, Merlano M, Sponghini A, Moretti G, Mainardi L, Bossi P.
Prognostic role of pre-treatment magnetic resonance imaging (MRI)-based radiomic analysis in effectively cured head and neck squamous cell carcinoma
Alfieri S, Romanò R, Bologna M, Calareso G, Corino V, Mirabile A, Ferri A, Bellanti L, Poli T, Marcantoni A, Grosso E, Tarsitano A, Battaglia S, Blengio F, De Martino I, Valerini S, Vecchio S, Richetti A, Deantonio L, Martucci F, Grammatica A, Ravanelli M, Ibrahim T, Caruso D, Locati LD, Orlandi E, Bossi P, Mainardi L, Licitra LF.
Uncommon site of metastatis and prolonged survival in patients with anaplastic thyroid carcinoma: a systematic review of the literature
Mirabile A, Biafora M, Giordano L. et al.
Low skeletal muscle mass as predictor of postoperative complications and decreased overall survival in locally advanced head and neck squamous cell carcinoma: the role of ultrasound of rectus femoris muscle
Galli A, Colombo M, Carrara G, Lira Luce F, Paesano PL, Giordano L, Bondi S, Tulli M, Mirabile A, De Cobelli F, Bussi M.
Metabolism and Immune Modulation in Patients with Solid Tumors: Systematic Review of Preclinical and Clinical Evidence
Cancers (Basel). 2020;12(5):E1153. Published 2020 May 4. doi:10.3390/cancers12051153
Mirabile A, Rivoltini L, Daveri E, et al.
Head and Neck Cancer: Psychological and Psychosocial Effects
The Impact of Pain- Head and Neck Cancer, 2020 – Springer.
P. Bossi, M C Merlano, M G Ghi, G RInalkdi, F Casponigro, M Airoldi, A Farnesi, A Cassano, D Ferrari, A Mirabile, A Tosoni, D Galizia, G Moretti, G Calareso, A Vingiani, F Perrone, A Falletta, LF Licitra. A single-ar, open label multicenter, phase IIIb clinical trial with nuvolumab in subjects with recurrent or metastatic platinum-refractoru squamous cell carcinoma of the head and neck. Annals of Oncology, Volume 30, Issue Supplement_5, October 2019, 9. CE Fundakowski ; A Mirabile
Patients Selection for Immunotherapy in Solid Tumors: Overcome the Naïve Vision of a Single Biomarker
Biomed Res Int. 2019 Apr 24;2019:9056417. doi: 10.1155/2019/9056417. eCollection 2019. Review.
Signorelli D, Giannatempo P, Grazia G, Aiello MM, Bertolini F, Mirabile A, Buti S, Vasile E, Scotti V, Pisapia P, Cona MS, Rolfo C, Malapelle U, Group IY.
Prognostic factors in recurrent or metastatic squamous cell carcinoma of the head and neck
Head Neck. 2019 Jan 16.
Mirabile A, Miceli R, Calderone RG, Locati L, Bossi P, Bergamini C, Granata R, Perrone F, Mariani L, Licitra L.
Prevalence, characteristics, and treatment of fatigue in oncological cancer patients in Italy: a cross-sectional study of the Italian Network for Supportive Care in Cancer (NICSO)
(Network Italiano per le Cure di Supporto in Oncologia). Support Care Cancer. 2018 Aug 6. doi: 10.1007/s00520-018-4393-9.
Roila F1, Fumi G2, Ruggeri B3, Antonuzzo A4, Ripamonti C5, Fatigoni S2, Cavanna L6, Gori S7, Fabi A8, Marzano N9, Graiff C10, De Sanctis V11, Mirabile A12, Serpentini S13, Bocci C14, Pino MS15, Cilenti G16, Verusio C17, Ballatori E18; NICSO
Predictors of Patient-Reported Dysphagia Following IMRT Plus Chemotherapy in Oropharyngeal Cancer
Dysphagia. 2018 Jun 8. doi: 10.1007/s00455-018-9913-8.
Orlandi E1, Miceli R2, Infante G2, Mirabile A3, Alterio D4, Cossu Rocca M5, et al.

Do you need an appointment?

Contact us and we will take care of you.